The Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals

Not yet recruiting

• Conditions: Urinary Tract Infections; Diagnostic Techniques and Procedures; Point-of-Care Testing; Anti-Bacterial Agents; Registry; Clinical Decision-making; Urinalysis

• Registration Number: NCT06750666
• Lead Sponsor: Jacob Bodilsen

Brief Summary

The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:

How does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?

Specifically, does it change the following parameters:

* Number and severity of UTI infections (lower and upper UTI, non-severe and severe)

* Antibiotic prescription (overall, antibiotic classes, administration routes, duration, dosages)

* Number of urine cultures and number of positive urine cultures

* Risks of admission to intensive care units and 30-day mortality

* Risk of drug toxicity

* Length of hospital stay

* Risk of admission to intensive care unit

* 30-day risk of readmission after discharge

* 6-month risks of Clostridioides difficile enterocolitis and de novo antimicrobial resistance in cultures obtained during routine clinical care.

Researchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.

Researchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.

Since this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.

Detailed Description

BACKGROUND:

Urinary tract infections (UTIs) are a leading cause of antibiotic treatment and hospitalizations in Europe and the United States. Urine dipsticks are a widely used point-of-care test in hospitals, with over half of admitted patients in the North Denmark Region being screened using this method. They are considered an effective tool to rule out UTIs and aim to save resources by reducing unnecessary urine cultures and guiding initial antibiotic choice when used correctly. However, for reliable results, urine dipsticks require specific preanalytical conditions, such as a clean midstream sample retained in the bladder for 4-6 hours before voiding. These criteria are rarely met in clinical practice. Moreover, the prevalence of asymptomatic bacteriuria among hospitalized patients is about 45% which requires careful interpretation and correlation with specific symptoms of UTI by the clinician.

Although designed to rule out UTIs, studies suggest that urine dipsticks are often misused to rule them in, despite their low positive predictive value in hospital settings. This misuse may contribute to excessive antibiotic use. Furthermore, despite their generally high negative predictive value, a recent study in the North Denmark Region found that negative dipsticks cannot reliably exclude UTIs in symptomatic patients.

Due to these limitations, urine dipsticks were de-implemented throughout the North Denmark Region in August 2023 and February 2024. In September 2024, the Danish Society of Infectious Diseases and the Danish Society of Clinical Microbiology recommended discontinuing dipstick use in all Danish hospitals. However, the impact of de-implementing such a widely used point-of-care test remains unknown, raising questions about whether the advantages of this decision outweigh its potential drawbacks.

AIM This study aims to assess the impact of removing urine dipsticks in hospitals in the North Denmark Region.

HYPOTHESES

1. The incidence of urine cultures will decrease after the de-implementation of the urine dipstick.

2. The incidence of the ICD-10 codes, DN300 (acute cystitis), DN308C (recurrent cystitis), DN309 (unspecific cystitis), and DA419B (urosepsis) will decrease after the de-implementation of the urine dipstick.

3. The overall use of antibiotics as well as UTI-specific antibiotics, pivmecillinam, nitrofurantoin, sulfamethizol, and trimethoprim, will decrease after the de-implementation of the urine dipstick.

4. Risk of admission into the intensive care unit will remain unchanged before and after the de-implementation of the urine dipstick.

5. The average length of hospital stay and mortality rate will remain unchanged before and after the de-implementation of the urine dipstick.

6. Risk of early readmissions, defined as a return to an inpatient unit or emergency room within 30 days after the initial discharge, will remain the same before and after the de-implementation of the urine dipstick.

In a subpopulation of patients with positive urine cultures, the investigators hypothesize that:

1. The mortality rate and average length of stay will remain unchanged after the de-implementation of the urine dipstick.

2. The proportion of patients treated with antibiotics with uropathogenic coverage will remain the same before and after the de-implementation of the dipsticks (the UTI-specific antibiotics presented above and/or ampicillin/gentamicin, piperacillin/tazobactam or ciprofloxacin).

METHODS Design This study will be a registry-based interrupted time-series analysis utilizing data from the Business Intelligence Portal in the North Denmark Region. Data before and after the abolishment of the dipsticks will be extracted.

Setting Exposure The de-implementation of urine dipsticks in North Denmark Region in August 2023 (Aalborg) and February 2024 (Hjørring).

Study period Data will be extracted from both emergency rooms and inpatient units. The data extraction will start when the Business Intelligence Portal can extract data (preferably from 2019), and end at the latest update of conducting the study.

This study will include two control groups:

1. A comparable hospital cohort from the Central Denmark Region.

2. The total number of urine cultures requested by general practitioners in the North Denmark Region during the study period.

STATISTICS To avoid duplicates, the primary analysis will only include each patient's first admission during the study period.

Descriptive statistics: Incidence rates

Since hospitalized patients are an open cohort, the incidence rates (e.g. of antibiotic use), will be calculated using the following formula:

Monthly incidence rate of pivmecillinam use=((Number of unique persons treated with pivmecillinam))/(Amount of total person time in a month)=X pr.1000 patient days

Confidence intervals of the incidence rates will be calculated based on the Poisson distribution, and the standard error will be calculated as:

Standard error (log⁡〖rate)=1/√(number of cases)〗 The total incidence rates will be standardized using direct standardization based on the age distribution of the patient population as of September 2024 (the latest available data at the time of writing this protocol).

Mortality

Mortality rates will be calculated using the same methodology as presented above. In a supplementary analysis, the investigators will calculate the 30-day mortality risk:

30-day mortality risk=(Number of deaths within 30 days)/(Total number of admissions)=X %

And the case-fatality rate:

Case fatality=(Number of deaths in the hospital)/(Total number of admissions)=X %

Charlson Severity Index The medical history extracted up to 10 years before the index date, will be extracted to calculate the Charlson Comorbidity Index using standard methodology.

Comparisons The incidence and mortality rates in the North Denmark Region before and after the de-implementation of the dipstick will be compared using the principles of interrupted time series regression. This methodology offers the advantage of adjusting for seasonality. Furthermore, the rates in the North Denmark Region will be compared to those in the control groups.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-20
• Study First Submitted QC: 2024-12-20
• Study First Posted: 2024-12-27
• Last Update Submitted: 2024-12-27
• Last Update Posted: 2024-12-31
• Study Start: 2025-04
• Primary Completion: 2025-10
• Study Completion: 2026-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 480000

Inclusion Criteria

• All patients admitted to emergency rooms (≥18 years) from 2019 and forward.

Exclusion Criteria

• Patients directly admitted to an inpatient unit without first visiting an emergency room are excluded from the study.
• For the primary analysis, only the first admission will be included; subsequent admissions will be excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Monthly Incidence Rate of Urinary Tract Diagnoses (Composite Measure)	The monthly incidence will be calculated between January 2019 to end of the study (September 2025)	The monthly count of urinary tract infection diagnoses (ICD-10 codes: DN300, DN308C, DN309, DA419B) will be divided by the total person-time contributed by all admitted patients to the hospitals.; The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.
Monthly Incidence Rate of Urine Cultures (Composite Measure)	The monthly incidence will be calculated between January 2019 to end of the study period (September 2025)	The monthly count of urine cultures (including all cultures, both positive and negative) will be divided by the total person-time contributed by admitted patients. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.
Monthly Incidence Rate of Antibiotic Usage (Composite Measure)	The monthly incidence rate will be calculated between January 2019 to end of the study period (September 2025)	The monthly count of urinary tract infection-specific antibiotic use (pivmecillinam, nitrofurantoin, sulfamethizole, and trimethoprim) will be divided by the total person-time contributed by all admitted patients to the hospitals. The resulting incidence rate will be expressed as the number of cases per 1000 patient-days.
Monthly Mortality Rate (Composite Measure)	The monthly mortality rate will be calculated between January 2019 to end of the study period (September 2025)	The monthly count of deaths will be divided by the total person-time contributed by admitted patients. The resulting mortality rate will be expressed as the number of deaths per 1000 patient-days.
Monthly Incidence Rate of Readmissions (Composite Measure)	The monthly incidence rate of readmissions will be calculated between January 2019 and the end of the study period (September 2025)	The monthly count of readmissions, defined as a return to an inpatient unit or emergency room within 30 days after the initial discharge, will be divided by the total person-time contributed by admitted patients. The resulting incidence rate will be expressed as the number of readmissions per 1000 patient-days.
Median Length of Hospital Stay	The monthly median will be calculated from January 2019 to the end of the study period (September 2025).	The length of hospital stay will be measured in days for each admitted patient. The monthly median and interquartile range will be calculated over the study period.

Trial Locations

Locations (2)

Aalborg University Hospital; 🇩🇰 Aalborg, Denmark

North Denmark Regional Hospital; 🇩🇰 Hjørring, Denmark